The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence

Pharmacology and Therapeutics

Volumn 141, Issue 3, 2014, Pages 283-299

  Witkin, Jeffrey M ^a   Statnick, Michael A ^a   Rorick Kehn, Linda M ^a   Pintar, John E ^b   Ansonoff, Michael ^b   Chen, Yanyun ^a   Tucker, R Craig ^a   Ciccocioppo, Roberto ^c  

^a ELI LILLY AND COMPANY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Anxiety; Depression; Drug dependence; N OFQ; Nociceptin Orphanin FQ; Obesity; Stress

Indexed keywords

ALCOHOL; CENTRAL STIMULANT AGENT; NOCICEPTIN; NOCICEPTIN RECEPTOR; NOCISTATIN; OPIATE PEPTIDE; PROTEIN PRECURSOR;

ALCOHOLISM; ANTIDEPRESSANT ACTIVITY; ANXIETY; BIOLOGICAL FUNCTIONS; BODY WEIGHT; DEPRESSION; DRUG DEPENDENCE; FEEDING; HOMEOSTASIS; HUMAN; MENTAL DISEASE; MOOD; NONHUMAN; OBESITY; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW; STRESS;

(1S,3AS)-8- (2,3,3A,4,5,6-HEXAHYDRO-1H-PHENALEN-1-YL)-1-PHENYL-1,3,8-TRIAZA-SPIRO[4.5]DECAN-4-ONE, A NOP RECEPTOR AGONIST; (±)TRANS-1-[1-CYCLOOCTYLMETHYL-3-HYDROXYMETHYL-4-PIPERIDYL]-3-ETHYL-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE, A NOP RECEPTOR ANTAGONIST; 2-{3-[1-((1R)-ACENAPHTHEN-1-YL)PIPERIDIN-4-YL]-2,3-DIHYDRO-2-OXO-BENZIMIDAZOL-1-YL}-N-METHYLACETAMIDE, A NOP RECEPTOR AGONIST; 5-HT; 5-HYDROXYTRYPTAMINE OR SEROTONIN; 8-[BIS(2-METHYLPHENYL)-METHYL]-3-PHENYL-8-AZABICYCLO[3.2.1]OCTAN-3-OL; ACTH; ADRENOCORTICOTROPIC HORMONE; ALCOHOL-PREFERRING RATS; ANXIETY; BED; BED NUCLEUS OF STRIA TERMINALIS; BINGE EATING DISORDER; BNST; CALCITONIN GENE RELATED PEPTIDE; CEA; CENTRAL NUCLEUS OF THE AMYGDALA; CGRP; CONDITIONED PLACE PREFERENCE; CONDITIONED TASTE AVERSION; CORTICOTROPHIN-RELEASING FACTOR; CPP; CRF; CTA; DA; DEPRESSION; DOPAMINE; DRUG DEPENDENCE; ENDO-8-[BIS(2-CHLOROPHENYL)METHYL]-3-PHENYL-8-AZABICYCLO[3.2.1]OCTANE-3-CARBOXAMIDE, A NOP RECEPTOR AGONIST; EPSC; EXCITATORY POST-SYNAPTIC CURRENT; FORCED-SWIM TEST; FST; G-PROTEIN ACTIVATED, INWARDLY RECTIFYING K(+) CHANNEL; G-PROTEIN-COUPLED RECEPTOR; GIRK; GPCR; HPA; HYPOTHALAMIC-PITUITARY AXIS; J-113397; JTC-801; KNOCKOUT; KO; MAJOR DEPRESSIVE DISORDER; MARCHIGIAN SARDINIAN ALCOHOL-PREFERRING; MDD; MEDIAL PREFRONTAL CORTEX; MPFC; MSP; N-(4-AMINO-2-METHYLQUINOLIN-6-YL)-2-(4-ETHYLPHENOXYMETHYL)BENZAMIDE HYDROCHLORIDE, A NOP RECEPTOR ANTAGONIST; N/OFQ; NACC; NE; NEUROPEPTIDE Y; NOCICEPTIN OPIOID PEPTIDE OR NOCICEPTIN OPIOID PEPTIDE RECEPTOR; NOCICEPTIN/ORPHANIN FQ; NOCICEPTIN/ORPHANIN FQ (F: PHENYLALANINE, Q: GLUTAMINE, THE AMINO ACIDS THAT BEGIN AND END THE PEPTIDE SEQUENCE); NOP; NOREPINEPHRINE; NPY; NUCLEUS ACCUMBENS; OBESITY; OPIOID-RECEPTOR-LIKE; ORL; P RATS; POMC; PRO-OPIOMELANOCORTIN; RO 64-6198; SB-612111; SCH 221510; SCH 655842; STRESS; TAIL-SUSPENSION TEST; TST; UFP-101; VENTRAL TEGMENTAL AREA; VTA; W212393; [(-)-CIS-1-METHYL-7-[[4-(2,6-DICHLOROPHENYL)PIPERIDIN-1-YL]METHYL]-6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTEN-5-OL, A NOP RECEPTOR ANTAGONIST; [NPHE(1),ARG(14),LYS(15)]N/OFQ-NH(2), A NOP RECEPTOR ANTAGONIST;

ANIMALS; ANXIETY; DRUG DESIGN; HUMANS; MICE; MOOD DISORDERS; OBESITY; OPIOID PEPTIDES; RATS; RECEPTORS, OPIOID; STRESS, PSYCHOLOGICAL; SUBSTANCE-RELATED DISORDERS;

EID: 84892374382     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.10.011     Document Type: Review

References (206)

1. U.M. Anderberg, Z. Liu, L. Berglund, and F. Nyberg Plasma levels on nociceptin in female fibromyalgia syndrome patients Z Rheumatol 57 Suppl. 2 1998 77 80
2. W.M. Armstead Nociceptin/orphanin phenylalanine glutamine (FQ) receptor and cardiovascular disease Cardiovasc Ther 29 1 2011 23 28 10.1111/j.1755-5922. 2010.00241
3. H. Aujla, R. Cannarsa, P. Romualdi, R. Ciccocioppo, R. Martin-Fardon, and F. Weiss Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal Addict Biol 18 2010 467 479
4. M. Barrot, M. Marinelli, D.N. Abrous, F. Rouge-Pont, M. Le Moal, and P.V. Piazza Functional heterogeneity in dopamine release and in the expression of Fos-like proteins within the rat striatal complex Eur J Neurosci 11 1999 1155 1166
5. D. Bebawy, P. Marquez, S. Samboul, D. Parikh, A. Hamid, and K. Lutfy Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in mice Biol Psychiatry 68 2011 223 230
6. G.G. Blakley, L.A. Pohorecky, and D. Benjamin Behavioral and endocrine changes following antisense oligonucleotide-induced reduction in the rat NOP receptor Psychopharmacology (Berl) 171 4 2004 421 428 10.1007/s00213-003-1597-5
7. P. Bloms-Funke, C. Gillen, A.J. Schuettler, and S. Wnendt Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor Peptides 21 7 2000 1141 1146
8. J.A. Bodkin, G.L. Zornberg, S.E. Lukas, and J.O. Cole Buprenorphine treatment of refractory depression J Clin Psychopharmacol 15 1 1995 49 57
9. E.M. Bomberg, M.K. Grace, A.S. Levine, and P.K. Olszewski Functional interaction between nociceptin/orphanin FQ and alpha-melanocyte-stimulating hormone in the regulation of feeding Peptides 27 7 2006 1827 1834 10.1016/j.peptides.2006.02.007
10. S.M. Bouali, A. Fournier, S. St-Pierre, and F.B. Jolicoeur In vivo central actions of NPY(1-30), an N-terminal fragment of neuropeptide Y Peptides 15 5 1994 799 802
11. H. Brooks, C.D. Elton, D. Smart, D.J. Rowbotham, A.T. McKnight, and D.G. Lambert Identification of nociceptin in human cerebrospinal fluid: comparison of levels in pain and non-pain states Pain 78 1 1998 71 73
12. E.E. Brown, J.M. Finlay, J.T. Wong, G. Damsma, and H.C. Fibiger Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse J Pharmacol Exp Ther 256 1 1991 119 126
13. S.M. Brown, M. Holtzman, T. Kim, and E.D. Kharasch Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active Anesthesiology 115 6 2011 1251 1260
14. M.E. Carroll, G.N. Carmona, S.A. May, S. Buzalsky, and C. Larson Buprenorphine's effects on self-administration of smoked cocaine base and orally delivered phencyclidine, ethanol and saccharin in rhesus monkeys J Pharmacol Exp Ther 261 1 1992 26 37
15. M.E. Carroll, and S.T. Lac Effects of buprenorphine on self-administration of cocaine and a nondrug reinforcer in rats Psychopharmacology (Berl) 106 4 1992 439 446
16. M.J. Chee, C.J. Price, M.A. Statnick, and W.F. Colmers Nociceptin/orphanin FQ suppresses the excitability of neurons in the ventromedial nucleus of the hypothalamus J Physiol 589 Pt 13 2011 3103 3114 10.1113/jphysiol.2011.208819
17. X. Chen, D.B. McClatchy, E.B. Geller, L. Liu-Chen, R.J. Tallarida, and M.W. Adler Possible mechanism of hypothermia induced by intracerebroventricular injection of orphanin FQ/nociceptin Brain Res 904 2 2001 252 258
18. S.A. Chen, L.E. O'Dell, M.E. Hoefer, T.N. Greenwell, E.P. Zorrilla, and G.F. Koob Unlimited access to heroin self-administration: independent motivational markers of opiate dependence Neuropsychopharmacology 31 12 2006 2692 2707 (d)
19. L.C. Chiou, H.J. Lee, Y.C. Ho, S.P. Chen, Y.Y. Liao, C.H. Ma, and S.J. Wang Orexins/hypocretins: pain regulation and cellular actions Curr Pharm Des 16 28 2010 3089 3100
20. L.C. Chiou, Y.Y. Liao, P.C. Fan, P.H. Kuo, C.H. Wang, C. Riemer, and E.P. Prinssen Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications Curr Drug Targets 8 1 2007 117 135
21. S. Chung, S. Pohl, J. Zeng, O. Civelli, and R.K. Reinscheid Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance J Pharmacol Exp Ther 318 1 2006 262 267 10.1124/jpet.106.103960
22. R. Ciccocioppo It has been reported that N/OFQ blocks the anxiogenic-like effect of CRF and abolishes the anorectic effect of restraint stress and CRF within the BNST and the CeA 2003
23. R. Ciccocioppo, S. Angeletti, P.P. Sanna, F. Weiss, and M. Massi Effect of nociceptin/orphanin FQ on the rewarding properties of morphine Eur J Pharmacol 404 2000 153 159
24. R. Ciccocioppo, M. Biondini, L. Antonelli, J. Wichmann, F. Jenck, and M. Massi Reversal of stress- and CRF-induced anorexia in rats by the synthetic nociceptin/orphanin FQ receptor agonist, Ro 64-6198 Psychopharmacology (Berl) 161 2 2002 113 119 10.1007/s00213-002-1020-7
25. R. Ciccocioppo, A. Cippitelli, D. Economidou, A. Fedeli, and M. Massi Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin- releasing factor to inhibit its anorectic effect Physiol Behav 82 1 2004 63 68 10.1016/j.physbeh.2004.04.035
26. R. Ciccocioppo, D. Economidou, R. Rimondini, W. Sommer, M. Massi, and M. Heilig Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system Biol Psychiatry 61 1 2007 4 12 10.1016/j.biopsych.2006.01.006
27. R. Ciccocioppo, and P. Hyytia The genetics of alcoholism: learning from 50 years of research Addict Biol 11 2006 193
28. R. Ciccocioppo, R. Martin-Fardon, F. Weiss, and M. Massi Nociceptin/orphanin FQ inhibits stress- and CRF-induced anorexia in rats Neuroreport 12 6 2001, 1145 1149
29. R. Ciccocioppo, I. Panocka, C. Polidori, D. Regoli, and M. Massi Effect of nociceptin on alcohol intake in alcohol-preferring rats Psychopharmacology (Berl) 141 1999 220 224
30. O. Civelli The orphanin FQ/nociceptin (OFQ/N) system Results Probl Cell Differ 46 2008 1 25 10.1007/400-2007-057
31. M. Corbani, C. Gonindard, and J.C. Meunier Ligand-regulated internalization of the opioid receptor-like 1: a confocal study Endocrinology 145 6 2004 2876 2885
32. S.F. Cordery, A. Taverner, I.E. Ridzwan, R.H. Guy, M.B. Delgado-Charro, S.M. Husbands, and C.P. Bailey A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm Addict Biol 2012 10.1111/adb.12020
33. M.T. Cruz, M.A. Herman, M. Kallupi, and M. Roberto Nociceptin/orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala is enhanced after chronic ethanol exposure Biol Psychiatry 71 2012 666 676
34. C. D'Addario, F.F. Caputi, R. Rimondini, O. Gandolfi, E. Del Borrello, S. Candeletti, and P. Romualdi Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related genes in rat brain Addict Biol 18 3 2013 425 433 10.1111/j.1369-1600.2011.00326.x
35. T. Darland, M.M. Heinricher, and D.K. Grandy Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more Trends Neurosci 21 1998 215 221
36. F.M. Dautzenberg, J. Wichmann, J. Higelin, G. Py-Lang, C. Kratzeisen, P. Malherbe, and F. Jenck Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo J Pharmacol Exp Ther 298 2 2001 812 819
37. D.P. Devine, M.T. Hoversten, Y. Ueda, and H. Akil Nociceptin/orphanin FQ content is decreased in forebrain neurones during acute stress J Neuroendocrinol 15 1 2003 69 74
38. D.P. Devine, S.J. Watson, and H. Akil Nociceptin/orphanin FQ regulates neuroendocrine function of the limbic-hypothalamic-pituitary-adrenal axis Neuroscience 102 3 2001 541 553
39. G. Di Chiara, and V. Bassareo Reward system and addiction: what dopamine does and doesn't do Curr Opin Pharmacol 7 2007 69 76
40. A. Di Giannuario, and S. Pieretti Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats Peptides 21 2000 1125 1130
41. H. Dueñas, A.J. Brnabic, A. Lee, A.L. Montejo, S. Prakash, M.L. Casimiro-Querubin, and J. Raskin Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period Int J Psychiatry Clin Pract 15 4 2011 242 254 10.3109/13651501.2011.590209
42. M. Duzzioni, F.S. Duarte, L.R. Leme, E.C. Gavioli, and T.C. De Lima Anxiolytic-like effect of central administration of NOP receptor antagonist UFP-101 in rats submitted to the elevated T-maze Behav Brain Res 222 1 2011 206 211 10.1016/j.bbr.2011.03.056
43. D. Economidou, A. Cippitelli, S. Stopponi, S. Braconi, S. Clementi, and M. Ubaldi et al. Activation of brain NOP receptors attenuates acute and protracted alcohol withdrawal symptoms in the rat Alcohol Clin Exp Res 35 2011 747 755
44. D. Economidou, A. Fedeli, R.M. Fardon, F. Weiss, M. Massi, and R. Ciccocioppo Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats Peptides 27 12 2006 3299 3306
45. D. Economidou, A.C. Hansson, F. Weiss, A. Terasmaa, W.H. Sommer, and A. Cippitelli et al. Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat Biol Psychiatry 64 2008 211 218
46. D. Economidou, F. Policani, T. Angellotti, M. Massi, T. Terada, and R. Ciccocioppo Effect of novel NOP receptor ligands on food intake in rats Peptides 27 4 2006 775 783 10.1016/j.peptides.2005.08.014
47. H.M. Emrich, P. Vogt, A. Herz, and W. Kissling Antidepressant effects of buprenorphine Lancet 2 8300 1982 709
48. C. Ertsey, M. Hantos, G. Bozsik, and K. Tekes Plasma nociceptin levels are reduced in migraine without aura Cephalalgia 25 4 2005 261 266 10.1111/j.1468-2982.2004.00849
49. B. Farhang, L. Pietruszewski, K. Lutfy, and E.J. Wagner The role of the NOP receptor in regulating food intake, meal pattern, and the excitability of proopiomelanocortin neurons Neuropharmacology 59 3 2010 190 200 10.1016/j.neuropharm.2010.05.007
50. M. Farrell, A. Wodak, and L. Gowing Maintenance drugs to treat opioid dependence BMJ 344 2012 e2823 10.1136/bmj.e2823
51. F. Fernandez, M.A. Misilmeri, J.C. Felger, and D.P. Devine Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety Neuropsychopharmacology 29 1 2004 59 71 10.1038/sj.npp.1300308
52. B. Fioravanti, and T.W. Vanderah The ORL-1 receptor system: are there opportunities for antagonists in pain therapy? Curr Top Med Chem 8 16 2008 1442 1451
53. S. Florin, J. Meunier, and J. Costentin Autoradiographic localization of [3H]nociceptin binding sites in the rat brain Brain Res 880 1-2 2000 11 16
54. E.C. Gavioli, and G. Calo Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands Naunyn Schmiedebergs Arch Pharmacol 372 5 2006 319 330 10.1007/s00210-006-0035-8
55. E.C. Gavioli, and G. Calo' Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs Pharmacol Ther 140 2013 10 25
56. E.C. Gavioli, G. Marzola, R. Guerrini, R. Bertorelli, S. Zucchini, T.C. De Lima, and G. Calo Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test Eur J Neurosci 17 9 2003 1987 1990
57. E.C. Gavioli, G.A. Rae, G. Calo, R. Guerrini, and T.C. De Lima Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test Br J Pharmacol 136 5 2002 764 772 10.1038/sj.bjp.0704739
58. E.C. Gavioli, A. Rizzi, G. Marzola, S. Zucchini, D. Regoli, and G. Calo Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice Peptides 28 6 2007 1229 1239 10.1016/j.peptides.2007.04.012
59. E.C. Gavioli, and P.R. Romao NOP receptor ligands as potential agents for inflammatory and autoimmune diseases J Amino Acids 2011 2011 836569 10.4061/2011/836569
60. E.C. Gavioli, C.W. Vaughan, G. Marzola, R. Guerrini, V.A. Mitchell, S. Zucchini, T.C. De Lima, G.A. Rae, S. Salvadori, D. Regoli, and G. Calo' Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice Naunyn Schmiedebergs Arch Pharmacol 369 2004 547 553
61. 35S]-GTPgammaS binding in the rat brain Neuropeptides 40 2 2006 95 105 10.1016/j.npep.2005.11.002
62. N.W. Gilpin, and M. Roberto Neuropeptide modulation of central amygdala neuroplasticity is a key mediator of alcohol dependence Neurosci Biobehav Rev 36 2 2012, Feb 873 888
63. C. Goeldner, D. Reiss, B.L. Kieffer, and A.M. Ouagazzal Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior Hippocampus 20 8 2010 911 916 10.1002/hipo.20760
64. C. Goeldner, W. Spooren, J. Wichmann, and E.P. Prinssen Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair Psychopharmacology (Berl) 222 2 2012, Jul 203 214
65. D. Grandi, M. Massi, R. Guerrini, G. Calo, and G. Morini Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon Life Sci 89 19-20 2011 735 740 10.1016/j.lfs.2011.08.015
66. M.K. Green, E.V. Barbieri, B.D. Brown, K.W. Chen, and D.P. Devine Roles of the bed nucleus of stria terminalis and of the amygdala in N/OFQ-mediated anxiety and HPA axis activation Neuropeptides 41 6 2007 399 410 10.1016/j.npep.2007.09.002
67. M.K. Green, and D.P. Devine Nociceptin/orphanin FQ and NOP receptor gene regulation after acute or repeated social defeat stress Neuropeptides 43 6 2009 507 514 10.1016/j.npep.2009.08.003
68. M.K. Greenwald, C.E. Johanson, D.E. Moody, J.H. Woods, M.R. Kilbourn, R.A. Koeppe, C.R. Schuster, and J.K. Zubieta Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers Neuropsychopharmacology 28 11 2003, Nov 2000 2009
69. G. Griebel, G. Perrault, and D.J. Sanger Orphanin FQ, a novel neuropeptide with anti-stress-like activity Brain Res 836 1-2 1999 221 224
70. H. Gu, D. Hu, X.R. Hong, J. Mao, Y. Cui, N. Hui, and J.Y. Sha Changes and significance of orphanin and serotonin in patients with postpartum depression Zhonghua Fu Chan Ke Za Zhi 38 12 2003 727 728
71. M. Hallberg, and F. Nyberg Neuropeptide conversion to bioactive fragments - an important pathway in neuromodulation Curr Protein Pept Sci 4 1 2003 31 44
72. M.S. Harbuz, and S.L. Lightman Responses of hypothalamic and pituitary mRNA to physical and psychological stress in the rat J Endocrinol 122 3 1989 705 711
73. J.E. Hawkinson, M. Acosta-Burruel, and S.A. Espitia Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors Eur J Pharmacol 389 2-3 2000 107 114
74. J.P. Herman, and W.E. Cullinan Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis Trends Neurosci 20 2 1997 78 84
75. A. Herz Endogenous opioid systems and alcohol addiction Psychopharmacology (Berl) 129 1997 99 111
76. J.R. Homberg, J.D. Mul, E. de Wit, and E. Cuppen Complete knockout of the nociceptin/orphanin FQ receptor in the rat does not induce compensatory changes in mu, delta and kappa opioid receptors Neuroscience 163 1 2009 308 315 10.1016/j.neuroscience.2009.06.021
77. P. Huang, G.B. Kehner, A. Cowan, and L.Y. Liu-Chen Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist J Pharmacol Exp Ther 297 2 2001 688 695
78. J.J. Hwa, M.B. Witten, P. Williams, L. Ghibaudi, J. Gao, B.G. Salisbury, and E.M. Parker Activation of the NPY Y5 receptor regulates both feeding and energy expenditure Am J Physiol 277 5 Pt 2 1999 R1428 R1434
79. K. Ikeda, M. Watanabe, T. Ichikawa, T. Kobayashi, R. Yano, and T. Kumanishi Distribution of pre-pro-nociceptin/orphanin FQ mRNA and its receptor mRNA in developing and adult mouse central nervous systems J Comp Neurol 399 1998 139 151
80. F. Jenck, J.L. Moreau, J.R. Martin, G.J. Kilpatrick, R.K. Reinscheid, F.J. Monsma Jr., and O. Civelli Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress Proc Natl Acad Sci U S A 94 26 1997 14854 14858
81. F. Jenck, J. Wichmann, F.M. Dautzenberg, J.L. Moreau, A.M. Ouagazzal, J.R. Martin, and G. Kilpatrick A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat Proc Natl Acad Sci U S A 97 9 2000 4938 4943 10.1073/pnas.090514397
82. S.W. Johnson, and R.A. North Opioids excite dopamine neurons by hyperpolarization of local interneurons J Neurosci 12 1992 483 488
83. H.L. June, C.R. Cason, S.H. Chen, and M.J. Lewis Buprenorphine alters ethanol self-administration in rats: dose-response and time-dependent effects Psychopharmacology (Berl) 140 1 1998 29 37
84. J. Kamei, Y. Matsunawa, S. Miyata, S. Tanaka, and A. Saitoh Effects of nociceptin on the exploratory behavior of mice in the hole-board test Eur J Pharmacol 489 1-2 2004 77 87 10.1016/j.ejphar.2003.12.020
85. H.L. Kimmel, and S.G. Holtzman Mu opioid agonists potentiate amphetamine- and cocaine-induced rotational behavior in the rat J Pharmacol Exp Ther 282 2 1997 734 746
86. Y. Kimura, M. Fujita, J. Hong, T.G. Lohith, R.L. Gladding, S.S. Zoghbi, and R.B. Innis Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors J Nucl Med 52 10 2011 1638 1645 10.2967/jnumed.111.091181
87. G.F. Koob Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder Curr Top Behav Neurosci 13 2013 3 30 10.1007/7854-2011-129
88. T.A. Kosten, D.W. Marby, and E.J. Nestler Cocaine conditioned place preference is attenuated by chronic buprenorphine treatment Life Sci 49 24 1991 L201 L206
89. T.R. Kosten, C. Morgan, and T.A. Kosten Depressive symptoms during buprenorphine treatment of opioid abusers J Subst Abuse Treat 7 1 1990 51 54
90. T.R. Kosten, M.I. Rosen, R. Schottenfeld, and D. Ziedonis Buprenorphine for cocaine and opiate dependence Psychopharmacol Bull 28 1 1992 15 19
91. A. Köster, A. Montkowski, S. Schulz, E.M. Stube, K. Knaudt, F. Jenck, and R.K. Reinscheid Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice Proc Natl Acad Sci U S A 96 18 1999 10444 10449
92. J. Kotlinska, P. Rafalski, G. Biala, T. Dylag, K. Rolka, and J. Silberring Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats Eur J Pharmacol 474 2003 233 239
93. J. Kotlinska, J. Wichmann, A. Legowska, K. Rolka, and J. Silberring Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference Behav Pharmacol 13 2002 229 235
94. C.M. Kotz, J.E. Briggs, M.K. Grace, A.S. Levine, and C.J. Billington Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat Am J Physiol 275 2 Pt 2 1998 R471 R477
95. M. Krepuska, P. Sotonyi, C. Csobay-Novak, Z. Szeberin, I. Hartyanszky, E. Zima, and K. Tekes Plasma nociceptin/orphanin FQ levels are lower in patients with chronic ischemic cardiovascular diseases - a pilot study Regul Pept 169 1-3 2011 1 5 10.1016/j.regpep.2011.01.007
96. A. Kuzmin, N. Madjid, B. Johansson, L. Terenius, and S.O. Ogren The nociceptin system and hippocampal cognition in mice: a pharmacological and genetic analysis Brain Res 1305 Suppl. 2009 S7 S19 10.1016/j.brainres.2009.09. 075
97. A. Kuzmin, J. Sandin, L. Terenius, and S.O. Ogren Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone J Pharmacol Exp Ther 304 2003 310 318
98. J.E. Lachowicz, Y. Shen, F.J. Monsma Jr., and D.R. Sibley Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family J Neurochem 64 1 1995 34 40
99. D.G. Lambert The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential Nat Rev Drug Discov 7 8 2008 694 710 10.1038/nrd2572
100. T.M. Largent-Milnes, and T.W. Vanderah Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat 20 3 2010 291 305 10.1517/13543771003602004
101. J.D. Leggett, K.L. Dawe, D.S. Jessop, and A.J. Fulford Endogenous nociceptin/orphanin FQ system involvement in hypothalamic-pituitary-adrenal axis responses: relevance to models of inflammation J Neuroendocrinol 21 11 2009 888 897 10.1111/j.1365-2826.2009.01912.x
102. J.D. Leggett, M.S. Harbuz, D.S. Jessop, and A.J. Fulford The nociceptin receptor antagonist [Nphe1, Arg14, Lys15]nociceptin/orphanin FQ-NH2 blocks the stimulatory effects of nociceptin/orphanin FQ on the HPA axis in rats Neuroscience 141 4 2006 2051 2057 10.1016/j.neuroscience.2006.05.036
103. J.D. Leggett, D.S. Jessop, and A.J. Fulford The nociceptin/orphanin FQ antagonist UFP-101 differentially modulates the glucocorticoid response to restraint stress in rats during the peak and nadir phases of the hypothalamo-pituitary-adrenal axis circadian rhythm Neuroscience 147 3 2007 757 764 10.1016/j.neuroscience.2007.04.010
104. P.A. Lester, and J.R. Traynor Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes Brain Res 1073-1074 2006 290 296 10.1016/j.brainres.2005.12.066
105. X. Li, A.B. Need, M. Baez, and J.M. Witkin mGlu5 receptor antagonism is associated with antidepressant-like effects in mice J Pharmacol Exp Ther 319 2006 254 259
106. G. Li, Y. Zhang, E. Rodrigues, D. Zheng, M. Matheny, K.Y. Cheng, and P.J. Scarpace Melanocortin activation of nucleus of the solitary tract avoids anorectic tachyphylaxis and induces prolonged weight loss Am J Physiol Endocrinol Metab 293 1 2007 E252 E258 10.1152/ajpendo.00451.2006
107. T.G. Lohith, S.S. Zoghbi, C.L. Morse, M.F. Araneta, V.N. Barth, N.A. Goebl, and M. Fujita Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A J Nucl Med 53 3 2012 385 392 10.2967/jnumed.111.097162
108. S.X. Lu, G.A. Higgins, R.A. Hodgson, L.A. Hyde, R.A. Del Vecchio, D.H. Guthrie, and G.B. Varty The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane- 3-carboxami de (SCH 655842): comparison of efficacy and side effects across rodent species Eur J Pharmacol 661 1-3 2011 63 71 10.1016/j.ejphar.2011.04.034
109. C. Luscher, and M.A. Ungless The mechanistic classification of addictive drugs PLoS Med 3 2006 e437
110. K. Lutfy, T. Do, and N.T. Maidment Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats Psychopharmacology (Berl) 154 2001 1 7
111. K. Lutfy, S. Eitan, C.D. Bryant, Y.C. Yang, N. Saliminejad, W. Walwyn, and C.J. Evans Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors J Neurosci 23 32 2003 10331 10337
112. K. Lutfy, I. Khaliq, F.I. Carroll, and N.T. Maidment Orphanin FQ/nociceptin blocks cocaine-induced behavioral sensitization in rats Psychopharmacology (Berl) 164 2002 168 176
113. L. Ma, Z.J. Cheng, G.H. Fan, Y.C. Cai, L.Z. Jiang, and G. Pei Functional expression, activation and desensitization of opioid receptor-like receptor ORL1 in neuroblastoma × glioma NG108-15 hybrid cells FEBS Lett 403 1 1997 91 94
114. P. Marquez, J. Borse, A.T. Nguyen, A. Hamid, and K. Lutfy The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine Neuroscience 155 3 2008 597 602 10.1016/j.neuroscience.2008.06.027
115. M. Marti, S. Stocchi, F. Paganini, F. Mela, C. De Risi, G. Calo, and M. Morari Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex Br J Pharmacol 138 1 2003 91 98 10.1038/sj.bjp.0705005
116. A. Martin, R. Pilotto, G. Singer, and T.P. Oei The suppression of ethanol self injection by buprenorphine Pharmacol Biochem Behav 19 6 1983 985 986
117. R. Martin-Fardon, R. Ciccocioppo, M. Massi, and F. Weiss Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats Neuroreport 11 2000 1939 1943
118. R. Martin-Fardon, E.P. Zorrilla, R. Ciccocioppo, and F. Weiss Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin Brain Res 1314 2010 145 161 10.1016/j.brainres.2009.12.027
119. H. Matsushita, A. Ishihara, S. Mashiko, T. Tanaka, T. Kanno, H. Iwaasa, and A. Kanatani Chronic intracerebroventricular infusion of nociceptin/orphanin FQ produces body weight gain by affecting both feeding and energy metabolism in mice Endocrinology 150 6 2009 2668 2673 10.1210/en.2008-1515
120. F. Mela, M. Marti, L. Ulazzi, E. Vaccari, S. Zucchini, C. Trapella, and M. Morari Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex Eur J Neurosci 19 5 2004 1317 1324 10.1111/j.1460-9568.2004.03220.x
121. N.K. Mello, M.P. Bree, and J.H. Mendelson Comparison of buprenorphine and methadone effects on opiate self-administration in primates J Pharmacol Exp Ther 225 2 1983 378 386
122. N.K. Mello, S.E. Lukas, J.H. Mendelson, and J. Drieze Naltrexone-buprenorphine interactions: effects on cocaine self-administration Neuropsychopharmacology 9 3 1993 211 224
123. J.C. Meunier, C. Mollereau, L. Toll, C. Suaudeau, C. Moisand, and P. Alvinerie et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor Nature 377 6549 1995 532 535 10.1038/377532a0
124. Micioni Di Bonaventura MV, Ubaldi M, Liberati S, Ciccocioppo R, Massi M, Cifani C (2013) Caloric restriction increases the sensitivity to the hyperphagic effect of nociceptin/orphanin FQ limiting its ability to reduce binge eating in female rats.
125. J. Mika, I. Obara, and B. Przewlocka The role of nociceptin and dynorphin in chronic pain: implications of neuro-glial interaction Neuropeptides 45 4 2011 247 261 10.1016/j.npep.2011.03.002
126. J.S. Mogil, B. Kest, B. Sadowski, and J.K. Belknap Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay J Pharmacol Exp Ther. 276 2 1996 532 544
127. C. Mollereau, L. Mouledous, S. Lapalu, G. Cambois, C. Moisand, J.L. Butour, and J.C. Meunier Distinct mechanisms for activation of the opioid receptor-like 1 and kappa-opioid receptors by nociceptin A Mol Pharmacol 55 2 1999 324 331 Psychopharmacology (Berl). 2013 Jul;228(1):53-63. nd dynorphin A
128. I.D. Montoya, D.A. Gorelick, K.L. Preston, J.R. Schroeder, A. Umbricht, L.J. Cheskin, W.R. Lange, C. Contoreggi, R.E. Johnson, and P.J. Fudala Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence Clin Pharmacol Ther 75 1 2004, Jan 34 48
129. N.P. Murphy, Y. Lee, and N.T. Maidment Orphanin FQ/nociceptin blocks acquisition of morphine place preference Brain Res 832 1999 168 170
130. T. Nabeshima, Y. Noda, and T. Mamiya The role of nociceptin in cognition Brain Res 848 1-2 1999 167 173
131. P. Nativio, E. Pascale, A. Maffei, S. Scaccianoce, and F. Passarelli Effect of stress on hippocampal nociceptin expression in rat Stress 15 4 2012, Jul 378 384
132. F. Nava, E. Manzato, C. Leonardi, and A. Lucchini Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: preliminary results of an open randomized study Prog Neuropsychopharmacol Biol Psychiatry 32 8 2008 1867 1872 10.1016/j.pnpbp.2008.08.019
133. C. Nazzaro, M. Barbieri, K. Varani, L. Beani, R.J. Valentino, and A. Siniscalchi Swim stress enhances nociceptin/orphanin FQ-induced inhibition of rat dorsal raphe nucleus activity in vivo and in vitro: role of corticotropin releasing factor Neuropharmacology 58 2 2010, Feb 457 464
134. C. Nazzaro, M. Barbieri, K. Varani, L. Beani, R.J. Valentino, and A. Siniscalchi Swim stress enhances nociceptin/orphanin FQ-induced inhibition of rat dorsal raphe nucleus activity in vivo and in vitro: role of corticotropin releasing factor Neuropharmacology 58 2 2010 457 464 10.1016/j.neuropharm.2009. 09.004
135. 125I-[(14)Tyr]-orphanin FQ binding J Comp Neurol 412 1999 563 605
136. C.R. Neal Jr., A. Mansour, R.K. Reinscheid, H.-P. Nothacker, O. Civelli, and S.J. Watson Jr. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat J Comp Neurol 406 1999 503 547
137. J.R. Nicholson, H. Akil, and S.J. Watson Orphanin FQ-induced hyperphagia is mediated by corticosterone and central glucocorticoid receptors Neuroscience 115 2002 637 643
138. M. Nishi, T. Houtani, Y. Noda, T. Mamiya, K. Sato, T. Doi, and T. Sugimoto Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphanin FQ receptor EMBO J 16 8 1997 1858 1864 10.1093/emboj/16.8.1858
139. C.S. Norton, C.R. Neal, S. Kumar, H. Akil, and S.J. Watson Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems J Comp Neurol 444 4 2002, Mar 18 358 368
140. 2 on rat brain noradrenaline release in vivo and in vitro Neurosci Lett 303 2001 173 176
141. E. Okuda-Ashitaka, T. Minami, S. Tachibana, Y. Yoshihara, Y. Nishiuchi, T. Kimura, and S. Ito Nocistatin, a peptide that blocks nociceptin action in pain transmission Nature 392 6673 1998 286 289 10.1038/32660
142. M.C. Olianas, S. Dedoni, M. Boi, and P. Onali Activation of nociceptin/orphanin FQ-NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D(1) receptor signaling in rat nucleus accumbens and dorsal striatum J Neurochem 107 2 2008, Oct 544 556
143. P.K. Olszewski, C.J. Billington, and A.S. Levine Fos expression in feeding-related brain areas following intracerebroventricular administration of orphanin FQ in rats Brain Res 855 1 2000 171 175
144. P.K. Olszewski, M.K. Grace, S.S. Fard, M. Le Greves, A. Klockars, M. Massi, and A.S. Levine Central nociceptin/orphanin FQ system elevates food consumption by both increasing energy intake and reducing aversive responsiveness Am J Physiol Regul Integr Comp Physiol 299 2 2010 R655 R663 10.1152/ajpregu.00556.2009
145. P.K. Olszewski, M.K. Grace, J.B. Sanders, C.J. Billington, and A.S. Levine Effect of nociceptin/orphanin FQ on food intake in rats that differ in diet preference Pharmacol Biochem Behav 73 3 2002 529 535
146. P.K. Olszewski, and A.S. Levine Minireview: Characterization of influence of central nociceptin/orphanin FQ on consummatory behavior Endocrinology 145 6 2004 2627 2632 Epub 2004 Mar 24. Review. Erratum in: Endocrinology, 146(5), 2005, 2453
147. A.M. Ouagazzal, J.L. Moreau, M. Pauly-Evers, and F. Jenck Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene Behav Brain Res 144 1-2 2003, Sep 15 111 117
148. V.W. Pike, K.S. Rash, Z. Chen, C. Pedregal, M.A. Statnick, Y. Kimura, and R.B. Innis Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography J Med Chem 54 8 2011 2687 2700 10.1021/jm101487v
149. F.M. Placenza, H. Rajabi, and J. Stewart Effects of chronic buprenorphine treatment on levels of nucleus accumbens glutamate and on the expression of cocaine-induced behavioral sensitization in rats Psychopharmacology (Berl) 200 3 2008 347 355 10.1007/s00213-008-1210-z
150. C. Polidori, G. Calo, R. Ciccocioppo, R. Guerrini, D. Regoli, and M. Massi Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist Psychopharmacology (Berl) 148 4 2000 430 437
151. J.D. Pomonis, C.J. Billington, and A.S. Levine Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats Neuroreport 8 1 1996 369 371
152. Preiss, K., Brennan, L., & Clarke, D. (2013). 12052. (Epub ahead of print).
153. K. Preiss, L. Brennan, and D. Clarke A systematic review of variables associated with the relationship between obesity and depression Obes Rev 2013, Jun 30 10.1111/obr
154. D.O. Procopio, L.M. Saba, H. Walter, O. Lesch, K. Skala, G. Schlaff, and B. Tabakoff Genetic markers of comorbid depression and alcoholism in women Alcohol Clin Exp Res 37 6 2013 896 904 10.1111/acer.12060
155. M.J. Przydzial, and L.K. Heisler Nociceptin/orphanin FQ peptide receptor as a therapeutic target for obesity Mini Rev Med Chem 8 8 2008 796 811
156. W. Raffaeli, B.G. Samolsky Dekel, D. Landuzzi, A. Caminiti, D. Righetti, M. Balestri, and S. Candeletti Nociceptin levels in the cerebrospinal fluid of chronic pain patients with or without intrathecal administration of morphine J Pain Symptom Manage 32 4 2006 372 377 10.1016/j.jpainsymman.2006.05.013
157. J.P. Redrobe, G. Caló, D. Regoli, and R. Quirion Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test Naunyn Schmiedebergs Arch Pharmacol 365 2002 164 167
158. R.K. Reinscheid, and O. Civelli The orphanin FQ/nociceptin knockout mouse: a behavioral model for stress responses Neuropeptides 36 2-3 2002 72 76
159. R.K. Reinscheid, J. Higelin, R.A. Henningsen, F.J. Monsma Jr., and O. Civelli Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities J Biol Chem 273 3 1998 1490 1495
160. R.K. Reinscheid, H.P. Nothacker, A. Bourson, A. Ardati, R.A. Henningsen, J.R. Bunzow, and O. Civelli Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor Science 270 5237 1995 792 794
161. A. Rizzi, E.C. Gavioli, G. Marzola, B. Spagnolo, S. Zucchini, R. Ciccocioppo, C. Trapella, D. Regoli, and G. Calò Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8, 9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies J Pharmacol Exp Ther 321 3 2007, Jun 968 974
162. A. Rizzi, S. Molinari, M. Marti, G. Marzola, and G. Calo Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies Neuropharmacology 60 4 2011 572 579 10.1016/j.neuropharm.2010.12.010
163. T.E. Robinson, and K.C. Berridge The neural basis of drug craving: an incentive-sensitization theory of addiction Brain Res Rev 18 1993 247 291
164. D. Rodi, C. Polidori, G. Bregola, S. Zucchini, M. Simonato, and M. Massi Pro-nociceptin/orphanin FQ and NOP receptor mRNA levels in the forebrain of food deprived rats Brain Res 957 2 2002 354 361
165. D. Rodi, S. Zucchini, M. Simonato, C. Cifani, M. Massi, and C. Polidori Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis Psychopharmacology (Berl) 196 2008 523 531
166. L.M. Rorick-Kehn, J.M. Witkin, M.A. Statnick, E.L. Eberle, J.H. McKinzie, S.D. Kahl, B.M. Forster, C.J. Wong, X. Li, R.S. Crile, D.B. Shaw, A.E. Sahr, B.L. Adams, S.J. Quimby, N. Diaz, A. Jimenez, C. Pedregal, C.H. Mitch, K.L. Knopp, W.H. Anderson, J.W. Cramer, and D.L. McKinzie LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders Neuropharmacology 77C 2014 131 144
167. S. Röver, Geo Adam, Andrea M. Cesura, Guido Galley, François Jenck, Frederick J. Monsma Jr., ‡. Jürgen Wichmann, and M. Frank Dautzenberg high-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor J Med Chem 43 2000 1329 1338
168. K. Rutten, J. De Vry, W. Bruckmann, and T.M. Tzschentke Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats Drug Alcohol Depend 114 2011 253 256
169. K. Sakoori, and N.P. Murphy Endogenous nociceptin (orphanin FQ) suppresses basal hedonic state and acute reward responses to methamphetamine and ethanol, but facilitates chronic responses Neuropsychopharmacology 33 2008 877 891
170. K. Sakoori, and N.P. Murphy Enhanced nicotine sensitivity in nociceptin/orphanin FQ receptor knockout mice Neuropharmacology 56 2009 896 904
171. R.S. Schottenfeld, J. Pakes, D. Ziedonis, and T.R. Kosten Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans Biol Psychiatry 34 1-2 1993 66 74
172. G.M. Scoto, G. Arico, A. Iemolo, G. Ronsisvalle, and C. Parenti Selective inhibition of the NOP receptor in the ventrolateral periaqueductal gray attenuates the development and the expression of tolerance to morphine-induced antinociception in rats Peptides 31 2010 696 700
173. A. Serrano-Gomez, J.P. Thompson, and D.G. Lambert Nociceptin/orphanin FQ in inflammation and sepsis Br J Anaesth 106 1 2011 6 12 10.1093/bja/aeq337
174. H.R. Sim, T.Y. Choi, H.J. Lee, E.Y. Kang, S. Yoon, P.L. Han, and J.H. Baik Role of dopamine D2 receptors in plasticity of stress-induced addictive behaviours Nat Commun 4 2013 1579 10.1038/ncomms2598
175. 3H]-5HT release from rat cerebral cortex slices Br J Pharmacol 128 1999 119 123
176. A. Siniscalchi, D. Rodi, M. Morari, M. Marti, S. Cavallini, S. Marino, L. Beani, and C. Bianchi Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro Br J Pharmacol 136 2002 1178 1184
177. R.E. Sorge, H. Rajabi, and J. Stewart Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement Neuropsychopharmacology 30 9 2005 1681 1692 10.1038/sj.npp.1300712
178. R.E. Sorge, and J. Stewart The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration Psychopharmacology (Berl) 188 1 2006 28 41 10.1007/s00213-006-0485-1
179. A. Spadaro, A. Ajello, C. Luigiano, C. Morace, M.L. Resta, G. Berlinghieri, and M.A. Freni Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma World J Gastroenterol 12 29 2006 4716 4720
180. S. Spampinato, M. Baiula, and M. Calienni Agonist-regulated internalization and desensitization of the human nociceptin receptor expressed in CHO cells Curr Drug Targets 8 1 2007, Jan 137 146
181. A.L. Stotts, C.L. Dodrill, and T.R. Kosten Opioid dependence treatment: options in pharmacotherapy Expert Opin Pharmacother 10 2009 1727 1740
182. T.R. Stratford, M.R. Holahan, and A.E. Kelley Injections of nociceptin into nucleus accumbens shell or ventromedial hypothalamic nucleus increase food intake Neuroreport 8 2 1997 423 426
183. T. Sugino, T. Shimazoe, N. Ikeda, and S. Watanabe Role of nociceptin and opioid receptor-like-1 on entrainment function in the rat suprachiasmatic nucleus Neuroscience 137 2006 537 544
184. R. Tao, Z. Ma, M.M. Thakkar, R.W. McCarley, and S.B. Auerbach Nociceptin/orphanin FQ decreases serotonin efflux in the rat brain but in contrast to a kappa-opioid has no antagonistic effect on mu-opioid-induced increases in serotonin efflux Neuroscience 147 1 2007, Jun 15 106 116
185. L. Terenius, J. Sandin, and T. Sakurada Nociceptin/orphanin FQ metabolism and bioactive metabolites Peptides 21 7 2000 919 922
186. J.M. Tetrault, and D.A. Fiellin Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals Drugs 72 2 2012 217 228 10.2165/11597520-000000000-00000
187. H. Uchiyama, A. Toda, T. Hiranita, S. Watanabe, and R. Eyanagi Role of amygdaloid nuclei in the anxiolytic-like effect of nociceptin/orphanin FQ in rats Neurosci Lett 431 1 2008, Jan 24 66 70
188. H. Ueda, T. Yamaguchi, S. Tokuyama, M. Inoue, M. Nishi, and H. Takeshima Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene Neurosci Lett 237 1997 136 138
189. G.B. Varty, L.A. Hyde, R.A. Hodgson, S.X. Lu, M.F. McCool, T.M. Kazdoba, R.A. Del Vecchio, D.H. Guthrie, A.J. Pond, M.E. Grzelak, X. Xu, W.A. Korfmacher, D. Tulshian, E.M. Parker, and G.A. Higgins Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species Psychopharmacology (Berl) 182 2005 132
190. G.B. Varty, S.X. Lu, C.A. Morgan, M.E. Cohen-Williams, R.A. Hodgson, A. Smith-Torhan, H. Zhang, A.B. Fawzi, M.P. Graziano, G.D. Ho, J. Matasi, D. Tulshian, V.L. Coffin, and G.J. Carey The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]- 3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510) J Pharmacol Exp Ther 326 2008 672 682
191. C.W. Vaughan, and M.J. Christie Increase by the ORL1 (opioid receptor-like 1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones Br J Pharmacol 117 1996 1609 1611
192. G. Vitale, R. Arletti, V. Ruggieri, C. Cifani, and M. Massi Anxiolytic-like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats Peptides 27 9 2006, Sep 2193 2200
193. G. Vitale, V. Ruggieri, M. Filaferro, C. Frigeri, S. Alboni, F. Tascedda, N. Brunello, R. Guerrini, C. Cifani, and M. Massi Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats Psychopharmacology (Berl) 207 2 2009, Dec 173 189
194. M. Volta, R. Viaro, C. Trapella, M. Marti, and M. Morari Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity Exp Neurol 228 1 2011 126 137 10.1016/j.expneurol.2010.12.024
195. + conductance Neuroendocrinology 67 1998 73 82
196. J.R. Walker, M. Spina, L. Terenius, and G.F. Koob Nociceptin fails to affect heroin self-administration in the rat Neuroreport 9 1998 2243 2247
197. L.N. Wang, L.F. Liu, J.X. Zhang, and G.F. Zhao Plasma levels of nociceptin/orphanin FQ in patients with bipolar disorders and health adults Zhonghua Yi Xue Za Zhi 89 13 2009 916 918
198. S. Wee, L.F. Vendruscolo, K.K. Misra, J.E. Schlosburg, and G.F. Koob A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence Sci Transl Med 4 146 2012 146ra110
199. J. Wichmann, Geo Adam, Stephan Röver, Michael Hennig, Michelangelo Scalone, Andrea M. Cesura, Frank M. Dautzenberg, and François Jenck Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3, 8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties Eur J Med Chem 35 2000 839 851
200. R.A. Wise, and P.P. Rompre Brain dopamine and reward Annu Rev Psychol 40 1989 191 225
201. S. Wnendt, T. Krüger, E. Janocha, D. Hildebrandt, and W. Englberger Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay Mol Pharmacol 56 2 1999, Aug 334 338
202. L. Yuan, Z. Han, J.K. Chang, and J.S. Han Accelerated release and production of orphanin FQ in brain of chronic morphine tolerant rats Brain Res 826 1999 330 334
203. N.T. Zaveri The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications Curr Top Med Chem 11 9 2011 1151 1156
204. L.L. Zhang, H.P. Zheng, C. Ma, Z.G. He, and C.D. Zheng The plasma orphanin FQ in patients with depression before and after treatment Chin J Psychiatry 42 3 2009 138 144
205. Y. Zhang, E. Rodrigues, G. Li, Y. Gao, M. King, C.S. Carter, and P.J. Scarpace Simultaneous POMC gene transfer to hypothalamus and brainstem increases physical activity, lipolysis and reduces adult-onset obesity Eur J Neurosci 33 8 2011 1541 1550 10.1111/j.1460-9568.2011.07633.x
206. R.J. Zhao, R.S. Woo, M.S. Jeong, B.S. Shin, D.G. Kim, and K.W. Kim Orphanin FQ/nociceptin blocks methamphetamine place preference in rats Neuroreport 14 2003 2383 2385